Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Respiratory muscle weakness results with decreased exercise capacity, worse fatigue, dyspnea and quality of life in patients with sarcoidosis. However, no study investigated the effects of inspiratory muscle training (IMT), therefore effects of IMT on outcomes in patients with sarcoidosis were investigated.
Patients were diagnosed with sarcoidosis according to the criteria of the latest American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous (WASOG) Disorders statement on sarcoidosis. Primary outcome measurement was respiratory muscle strength, secondary outcomes were, exercise capacity quality of life, fatigue and depression.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment group | Active Comparator | Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device . |
|
| Control group | Sham Comparator | Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device . |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inspiratory muscle training | Device | Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP). The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload. The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department. |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum inspiratory and expiratory muscle strength (MIP, MEP) | Mouth pressure device | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Exercise Capacity | Six-minute walk test (6MWT) | 6 weeks |
| Maximal Exercise Capacity | Modified incremental shuttle walk test (ISWT) | 6 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Müşerrefe Nur Karadallı, MSc. | Gazi University | Study Chair |
| Burcu Camcıoğlu, MSc. | Gazi University | Principal Investigator |
| Meral Boşnak Güçlü, PhD | Gazi University | Study Director |
| Nurdan Köktürk, MD | Gazi University | Principal Investigator |
| Haluk Türktaş, MD | Gazi University | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15618580 | Result | Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, Demedts MG, Decramer M. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005 Jan;60(1):32-8. doi: 10.1136/thx.2004.022244. | |
| 17099029 | Result | Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Muller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest. 2006 Nov;130(5):1496-502. doi: 10.1378/chest.130.5.1496. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012507 | Sarcoidosis |
| ID | Term |
|---|---|
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006968 | Hypersensitivity, Delayed |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Sham inspiratory muscle training | Device | Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England). The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department. |
|
| Fatigue | Fatigue Severity Scale (FSS) | 6 weeks |
| Pulmonary function and diffusing capacity | Spirometry | 6 weeks |
| Peripheral muscle strength | Hand-held dynamometer | 6 weeks |
| Dyspnea | Modified Borg and Modified Medical Research Council (MMRC) dyspnea scales | 6 weeks |
| Depression | Montgomery Asberg Depression Rating Scale (MADRS)) | 6 weeks |
| Quality of life | Saint George's Respiratory Questionnaire (SGRQ) (Turkish versions of all scales) | 6 weeks |
| 11451823 | Result | Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001 Jul;120(1):102-8. doi: 10.1378/chest.120.1.102. |
| 9230229 | Result | Wirnsberger RM, Drent M, Hekelaar N, Breteler MH, Drent S, Wouters EF, Dekhuijzen PN. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J. 1997 Jul;10(7):1450-5. doi: 10.1183/09031936.97.10071450. |
| 26715771 | Derived | Karadalli MN, Bosnak-Guclu M, Camcioglu B, Kokturk N, Turktas H. Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial. Respir Care. 2016 Apr;61(4):483-94. doi: 10.4187/respcare.04312. Epub 2015 Dec 29. |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |